2020
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Klemen ND, Wang M, Rubinstein JC, Olino K, Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: e000341. PMID: 32209601, PMCID: PMC7103823, DOI: 10.1136/jitc-2019-000341.Peer-Reviewed Original ResearchConceptsCheckpoint inhibitorsOverall survivalMetastatic melanomaPrimary tumorLocal therapyCutaneous melanomaAnti-PD-1 antibodyAggressive multidisciplinary approachCutaneous primary tumorPrimary tumor histologyMedian overall survivalSingle institutional experienceRare melanoma subtypeMedian OSMetastatic diseaseProgressive diseaseAcral skinComplete responsePD-1PD-L1Uveal tractTumor histologyCombination therapyCTLA-4Longer survival
2019
Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.
Raj N, Zheng Y, Kelly V, Katz S, Chou J, Do R, Capanu M, Zamarin D, Ariyan C, Untch B, O'Reilly E, Gopalan A, Berger M, Olino K, Segal N, Reidy D. Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma. Journal Of Clinical Oncology 2019, 37: 4112-4112. DOI: 10.1200/jco.2019.37.15_suppl.4112.Peer-Reviewed Original ResearchAdvanced adrenocortical carcinomaSafety of pembrolizumabAdrenocortical carcinomaPD-L1Germline next-generation sequencingMedian tumor mutation burdenPhysician/patient decisionTumor PD-L1 positivityTumor PD-L1 statusMedian age 62Treatment-related AEsTumor PD-L1PD-L1 positivityPD-L1 statusSingle-center studyTumor mutation burdenAvailable tumor samplesMutations/megabaseECOG 0LFT elevationsMedian DoRMedian OSMedian PFSIntolerable toxicityPrimary endpoint